Skip to main content

Diabetes Mellitus: Pharmacotherapy- SGLT, Centrally Acting Dopamine Agonists & Bile Acid Sequestrants!

 PHARMACOTHERAPY:

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors (Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

7.SODIUM-GLUCOSE CO-TRANPORTER (SGLT-2) INHIBITORS

The drugs approved include Canagliflozin, Dapagliflozin, Empagliflozin.

Mechanism of Action:

  • Glucose is freely filtered buy the kidney glomeruli and is reabsorbed in the proximal convoluted tubules by the action of sodium glucose co-transporters (SGLT). SGLT accounts for 90% of the glucose reabsorption and its inhibition causes glycosuria in people with diabetes, lowering plasma glucose levels.

Dose:

Canagliflozin: 100 & 300mg- 100mg daily if usual dose. 300mg daily can be used if eGFR resulting in lowering HDL. 

Dapagliflozin: 3 & 10mg- 10 mg daily. 3mg daily in hepatic failure.

Empagliflozin: 10 & 25mg- 10mg daily. 25 mg daily can be used if necessary.


8.CENTRAL ACTING DOPAMINE AGONISTS

  • A quick release formulation of a central acting dopamine agonist Bromocriptine was approved by the FDA in May 2009 for the treatment of T2DM.

Mechanism of Action:

  • The exact mechanism of action of how bromocriptine regulates glycemic control is unknown, however, data indicates that bromocriptine administered in the morning improves insulin sensitivity and this is a likely result of its effect on dopamine oscillations.

Clinical use:

  • A modest A1c reduction of 0.1%-0.4% is expected from this drug.

Adverse Effects:

  • Rhinitis
  • Dizziness
  • Asthenia
  • Headache
  • Sinusitis
  • Constipation
  • Nausea

Dose:

  • When used to treat patients with T2DM, bromocriptine should be taken 2hr after waking up in the morning with food. 
  • The initial dose is 0.8mg, titrated up weekly until a maximum dosage of 4.8mg/day is achieved.

Contraindication:

  • It is contraindicated in patients with migraine and in women who are nursing.


9.BILE ACID SEQUESTRANTS

  • Colesevelam is the only bile acid sequestrant currently approved as the adjunctive therapy to improve glycemic control in conjunction with diet, exercise and insulin or oral agents for the treatment of T2 DM.

Mechanism of action:

It acts on the intestinal lumen to bind bile acid but whether this is the drugs only action that results in plasma glucose lowering or if a secondary systemic effect to bile acid binding is unknown.

Clinical use:

  • An A1c reduction of approximately 0.4% can be expected when added to metformin, sulfonylurea or insulin. 
  • FPG is reduced about 5-10mg/dL.
  • LDL cholesterol is reduced 12-16%

Dose:

  •   Dosing for T2DM is 6*625mg tablets daily which may be split into 3 tablets twice daily.

Adverse Effects:

  • Constipation
  • Dyspepsia
  • Drug-drug interactions with Levothyroxine, Glyburide, Oral contraceptives, Phenytoin, Warfarin, Digoxin
  • Malabsorption of fat-soluble vitamins A, D, E and K 

Labels:

Comments

Post a Comment

Popular posts from this blog

Intravenous Therapy!

 INTRAVENOUS THERAPY Definition: "Intravenous therapy or IV therapy is the giving of liquid substances into vein".  It can be intermittent or continuous; continuous administration called an Intravenous drip.  The word intravenous simply means "within vein" but is most commonly used to refer to IV therapy. Compared to other routes of administration, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Some medications, as well as blood transfusions and lethal injections can only be given intravenously. The simplest form of intravenous access is a syringe with an attached hole in needle. The needle is inserted through the skin into a vein, and the contents of the syringe are injected through the needle into the bloodstream. This is easily done with an arm vein, especially one of the metacarpal veins. Usually, it is necessary to use a constricting band first to make the vein bulge; once needle is in place, it is common to dra...
Post a Comment
Read more

Procedure of IV selection!

 IV DRUG THERAPY- SELECTION OF EQUIPMENTS AND INSERTION OF CATHETER Equipment: Canula selection: Select cannula based on purpose and duration of use and age of patient. Consider risk of infection and extravasation. Cannula made from polyurethanes are associated with decreased risk of phlebitis. Steel needles have higher risk of extravasation and should be avoided where tissue necrosis is likely if extravasation occurs.       2. Skin Prep: Antiseptic solution, use an aqueous based alternative if there is a known allergy to alcohol.       3. Other Equipment: Intravenous solution as ordered, torniquet, giving set, IV stand/pole, infusion pump, transparent occlusive dressing, tape or similar to secure cannula, gloves, paper bag.       4. Additional Equipment which may be required: Syring (5mL), sterile sodium chloride 0.9%, local anesthetics (in children), 3-way tap or triflow, short extension tube. Selection Of the Catheter Site: Generally ...
Post a Comment
Read more

Drug-Induced Ototoxicity!

 DRUG-INDUCED OTOTOXICITY What is drug Induced Ototoxicity? Drug-Induced ototoxicity can affect hearing (auditory or cochlear function0, balance (vestibular function) depending on the drug. Drugs of almost every class have been reported to produce tinnitus (sounds in ear), as have placebos. The following agents are associated with measurable changes in hearing or vestibular defect when administered systemically. 1. AMINOGLYCOSIDES: Aminoglycosides antibiotics can cause cochlear or vestibular toxicities. Cochlear toxicity: occurs as progressive hear loss, starting with highest tones and advancing to lower tones. Thus, considerable damage can occur before the patient recognizes it. S ymptoms of Vestibular damage : include;  Dizziness Vertigo Ataxia Both forms of ototoxicity are bilateral and potentially reversible, but permanent damage is common and can progress even after discontinuation of aminoglycosides. Clinically detectable ototoxicity in as many as 5% patients. Most amin...
Post a Comment
Read more